PT2101799E - Utilização de agentes anabólicos, agentes anticatabólicos, agentes antioxidantes, e analgésicos para proteção, tratamento e reparação de tecidos conjuntivos em seres humanos e animais - Google Patents

Utilização de agentes anabólicos, agentes anticatabólicos, agentes antioxidantes, e analgésicos para proteção, tratamento e reparação de tecidos conjuntivos em seres humanos e animais Download PDF

Info

Publication number
PT2101799E
PT2101799E PT78625076T PT07862507T PT2101799E PT 2101799 E PT2101799 E PT 2101799E PT 78625076 T PT78625076 T PT 78625076T PT 07862507 T PT07862507 T PT 07862507T PT 2101799 E PT2101799 E PT 2101799E
Authority
PT
Portugal
Prior art keywords
agents
analgesics
humans
animals
repair
Prior art date
Application number
PT78625076T
Other languages
English (en)
Inventor
Todd R Henderson
Carmelita Frondoza
Original Assignee
Nutramax Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutramax Lab Inc filed Critical Nutramax Lab Inc
Publication of PT2101799E publication Critical patent/PT2101799E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT78625076T 2006-12-06 2007-12-05 Utilização de agentes anabólicos, agentes anticatabólicos, agentes antioxidantes, e analgésicos para proteção, tratamento e reparação de tecidos conjuntivos em seres humanos e animais PT2101799E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/634,383 US20070141181A1 (en) 1998-02-13 2006-12-06 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals

Publications (1)

Publication Number Publication Date
PT2101799E true PT2101799E (pt) 2015-05-18

Family

ID=39492846

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78625076T PT2101799E (pt) 2006-12-06 2007-12-05 Utilização de agentes anabólicos, agentes anticatabólicos, agentes antioxidantes, e analgésicos para proteção, tratamento e reparação de tecidos conjuntivos em seres humanos e animais

Country Status (12)

Country Link
US (2) US20070141181A1 (pt)
EP (1) EP2101799B1 (pt)
JP (1) JP5606071B2 (pt)
AU (1) AU2007328265B2 (pt)
CA (1) CA2672108C (pt)
DK (1) DK2101799T3 (pt)
ES (1) ES2535213T3 (pt)
HK (1) HK1136202A1 (pt)
NZ (1) NZ577602A (pt)
PL (1) PL2101799T3 (pt)
PT (1) PT2101799E (pt)
WO (1) WO2008070086A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503730A (ja) * 2006-09-19 2010-02-04 ワイス エルエルシー 変形性関節症の治療のためのｌｘｒアゴニストの使用
JP5632162B2 (ja) 2007-06-01 2014-11-26 協和発酵バイオ株式会社 経口組成物
ES2325392B1 (es) * 2007-12-28 2010-06-24 Bioiberica, S.A. Composicion para el tratamiento de la artrosis.
US20110213236A1 (en) * 2008-08-06 2011-09-01 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
EP2391219A4 (en) * 2009-01-29 2013-03-06 Joshua D Levine METHOD FOR ADDING VEGETABLE SUBSTANCES / NUTRITIONAL AGGREGATES FOR PHARMACEUTICAL TREATMENT IN A PHARMACOTHERAPEUTIC TREATMENT
EP2968990A4 (en) * 2013-03-15 2016-08-24 Nutramax Lab Inc COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL
WO2016027230A1 (en) * 2014-08-20 2016-02-25 Kolinpharma S.P.A. A composition for the treatment of arthropathies and osteoarthritis
PL3280423T3 (pl) 2015-04-08 2023-12-27 Microvascular Health Solutions, LLC Kompozycje i sposoby do synergistycznego leczenia glikokaliksu
EP3586851A1 (en) 2018-06-27 2020-01-01 Nextraresearch S.r.l. Compositions for oral administration of pentosan polysulfate and chitosan in form of nanoparticles with improved intestinal absorption

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281173A (en) 1940-01-10 1942-04-28 Victor Insulators Inc Insulator and method of producing conducting coating thereon
US2881173A (en) * 1957-02-14 1959-04-07 Hoffmann La Roche Basic ethers of hydroxy anthraquinones
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
BE759520A (fr) * 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US3624114A (en) * 1969-12-18 1971-11-30 Jean V Morelle Fatty acid amido-methionine products
US3993756A (en) * 1973-05-09 1976-11-23 Takashi Kaneda Antilipemic agent containing a soybean oil fraction
GB1511302A (en) * 1974-04-15 1978-05-17 Univ Johns Hopkins Pharmaceutical compositions comprising amino acid analogues
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4333484A (en) * 1978-08-02 1982-06-08 Philip Morris Incorporated Modified cellulosic smoking material and method for its preparation
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
FR2543145B1 (fr) * 1983-03-24 1986-10-17 Sanofi Sa Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
JPS59187792A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質糖類誘導体の製法
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US5225192A (en) * 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
FR2572731B1 (fr) * 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
US4683298A (en) * 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
WO1986005204A1 (en) * 1985-03-04 1986-09-12 Sawai Pharmaceutical Co., Ltd. Novel tumor necrosis factor-inducing substance originating in acid-fast bacteria
KR890001236B1 (ko) * 1985-10-02 1989-04-28 화이자 인코포레이티드 소염제 조성물의 제조방법
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
CA1327354C (en) 1987-03-19 1994-03-01 David Cullis-Hill Anti-inflamatory compounds and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US5137712A (en) * 1990-08-31 1992-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
FR2671725B1 (fr) * 1991-01-23 1995-06-02 Coletica Complexe de polyose et d'acide gras, utilisation comme agent emulsionnant ou hydratant et composition emulsionnante ou hydratante en contenant.
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
FR2678632B1 (fr) * 1991-07-03 1994-09-02 Pharmascience Lab Procede de preparation de l'insaponifiable d'avocat permettant d'ameliorer sa teneur en l'une de ses fractions dite h.
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
NZ245989A (en) * 1992-02-28 1995-02-24 Lilly Industries Ltd Anthraquinone derivatives and pharmaceutical compositions
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
US5364845C1 (en) * 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
CA2159078A1 (en) * 1993-04-07 1994-10-13 Soili Peltonen Applications and methods for the preparation of fatty acid esters of polysaccharides
IT1264545B1 (it) * 1993-07-30 1996-10-02 Medidom Lab Procedimento per la preparazione della diacereina
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9417102D0 (en) * 1994-08-24 1994-10-12 Lilly Industries Ltd Pharmaceutical compounds
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
US6451771B1 (en) * 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
MXPA02000052A (es) * 1999-07-06 2003-07-21 Foodscience Corp Metodos y composiciones para el soporte, regeneracion y reparacion de tejidos conectivos.

Also Published As

Publication number Publication date
PL2101799T3 (pl) 2015-06-30
WO2008070086A2 (en) 2008-06-12
EP2101799A4 (en) 2010-11-17
DK2101799T3 (en) 2015-04-07
EP2101799A2 (en) 2009-09-23
US8568803B2 (en) 2013-10-29
WO2008070086A3 (en) 2008-11-27
US20100203177A1 (en) 2010-08-12
HK1136202A1 (en) 2010-06-25
AU2007328265A1 (en) 2008-06-12
US20070141181A1 (en) 2007-06-21
CA2672108C (en) 2016-10-25
CA2672108A1 (en) 2008-06-12
AU2007328265B2 (en) 2014-02-27
EP2101799B1 (en) 2015-01-21
ES2535213T3 (es) 2015-05-06
JP2010511708A (ja) 2010-04-15
NZ577602A (en) 2012-10-26
JP5606071B2 (ja) 2014-10-15

Similar Documents

Publication Publication Date Title
HK1136202A1 (en) Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
GB2461412B (en) Methods and compositions for reduction of side effects of therapeutic treatments
ZA200908711B (en) Methods and compositions for treating allergic diseases
IL198723A0 (en) Methods and compositions for therapeutic treatment
HK1245679A1 (zh) 用於治療皮膚疾病和病症的方法和組合物
ZA200807398B (en) Compositions and methods for enhancing the antioxidant status of animals
PL2349231T3 (pl) Kompozycje i metody leczenia chorób kopyta
EP1841505A4 (en) FORMULA IONES AND TREATMENTS FOR WELL-BEING
EP2056849A4 (en) METHODS AND COMPOSITIONS FOR TREATING IGE MEDIATED DISEASES
EP2124968A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY
PL3156057T3 (pl) Powlekany delmopinolem gryzak dla zwierząt do stosowania w zapobieganiu lub leczeniu halitozy
ZA200705881B (en) Formulations and treatments for well-being
GB0718918D0 (en) Compositions and methods for treating skin conditions
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
ZA200810199B (en) Rinse-off therapeutic agents for treating skin
EP2032151A4 (en) COMBINATION THERAPY PROCESS AND FORMULATION
EP2057997A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY
ZA200708279B (en) Dermatological compositions and salts for the treatment of dermatological diseases
ZA201001779B (en) Compositions and methods for treating collagen-mediated diseases
GB0614097D0 (en) Medical treatments and compounds and compositions for use therein
GB0614095D0 (en) Medical treatments and compounds and compositions for use therein
GB2468424B (en) Methods and compositions for reduction of side effects of therapeutic treatments
GB0512551D0 (en) Methods and therapeutic treatments
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents